CrossRef Text and Data Mining

Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.

p16 Hypermethylation and KRAS Mutation Are Independent Predictors of Cetuximab Plus FOLFIRI Chemotherapy in Patients with Metastatic Colorectal Cancer

Se Hyun Kim, Kyu Hyun Park, Sang Joon Shin, Kang Young Lee, Tae Il Kim, Nam Kyu Kim, Sun Young Rha, Jae Kyung Roh, Joong Bae Ahn

Cancer Research and Treatment. 2016;48(1):208-215. Published online 2015 April 24 DOI: https://doi.org/10.4143/crt.2014.314

P16(INK4A) Gene Hypermethylation and Kras Mutation are Independent Predictors of FolFiri and Cetuximab Chemotherapy in Patients with Metastatic Colorectal Cancer (MCRC)

S.H. Kim, K.H. Park, S.J. Shin, K.Y. Lee, T.I. Kim, N.K. Kim, S.Y. Rha, J.K. Roh, J.B. Ahn

Annals of Oncology. 2012;23:ix185

Link1 Link2

<i>p16</i> Hypermethylation and <i>KRAS</i> Mutation Are Independent Predictors of Cetuximab Plus FOLFIRI Chemotherapy in Patients with Metastatic Colorectal Cancer

Se Hyun Kim, Kyu Hyun Park, Sang Joon Shin, Kang Young Lee, Tae Il Kim, Nam Kyu Kim, Sun Young Rha, Jae Kyung Roh, Joong Bae Ahn

Cancer Research and Treatment. 2016;48(1):208-215

Link1

Link2 Link3

Cetuximab plus FOLFIRI in first-line treatment of KRAS mutation-negative, EGFR-positive metastatic colorectal cancer

Jame Abraham

Community Oncology. 2012;9(10):304-306

Link1 Link2

Biweekly cetuximab plus FOLFIRI/irinotecan as first/second-line chemotherapy for patients with KRAS wild-type metastatic colorectal cancer: a retrospective analysis in Southwest Chinese population

Ye Chen, Dan Cao, Feng Bi, Qiu Li, Meng Qiu

Medical Oncology. 2014;31(5):

Link1

Link2 Link3

Retrospective Study as FirstLine Chemotherapy cetuximab plus FOLFIRI for unresectable KRAS wild type colorectal cancer

Norio Ureshino, Shinsuke Ogusu

Annals of Oncology. 2016;27:vii99

Link1 Link2 Link3

Cetuximab Plus Various Chemotherapy Regimens for Patients with KRAS Wild-Type Metastatic Colorectal Cancer

Payam Azadeh, Nafiseh Mortazavi, Arezoo Tahmasebi, Farnaz Hosseini Kamal, Kambiz Novin

Chemotherapy. 2015;61(1):51-56

Link1 Link2 Link3

Reply to FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer–subgroup analysis of patients with KRAS-mutated tumours in the randomised German AIO study KRK-0306

F. Pietrantonio, M.C. Garassino, V. Torri, F. de Braud

Annals of Oncology. 2012;23(10):2771-2772

Link1 Link2 Link3

Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab

T.J. Eberlein

Yearbook of Surgery. 2012;2012:322-323

Link1 Link2

A randomized Phase II clinical study of combining panitumumab and bevacizumab, plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) compared with FOLFIRI alone as second-line treatment for patients with metastatic colorectal cancer and KRAS mutation

Lijuan Luan, Yuguo Liu, Lijuan Luan

OncoTargets and Therapy. 2015;1061

Link1

Retrospective Analysis of Patients Treated with Cetuximab plus FOLFIRI for Previous Irinotecan-combined Chemotherapy in Metastatic Colorectal Cancer

Jae Woo Park, Sun-Mi Moon, Dae-Yong Hwang

Journal of the Korean Society of Coloproctology. 2008;24(5):345

Link1

This metadata service is kindly provided by CrossRef from May 29, 2014. Cancer Res Treat has participated in CrossRef Text and Data Mining service since October 29, 2014.